PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
WEBBayer presents positive results for Kerendia in late-stage heart failure study. Eli Lilly and HAYA Therapeutics enter metabolic condition partnership worth $1bn. Bayer and NextRNA Therapeutics enter oncology partnership worth $547m. J&J to expand cardiovascular capabilities with V-Wave acquisition worth up to $1.7bn.
Pfizer’s RSV vaccine granted MHRA approval to protect infants …
WEBNov 29, 2023 · Pfizer’s Abrysvo has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first respiratory syncytial virus (RSV) vaccine to protect both infants through maternal immunisation and older adults. RSV is a common contagious virus characterised by several mild, cold-like symptoms.
BeiGene and InnoRNA join to research novel mRNA therapies
WEBJul 7, 2022 · BeiGene and InnoRNA have announced a research collaboration to discover and develop novel mRNA therapies. The companies will jointly research a number of mRNA-LNP programmes, using InnoRNA’s LNP-based delivery technology and mRNA drug discovery along with BeiGene’s innovative technology platform to …
Precision medicine trial opens for patients with rare cancers
WEBNov 24, 2022 · Cancer Research UK, the University of Manchester and Roche have opened a multi-drug, precision medicine trial aiming to find out whether existing drugs could benefit patients with rare cancers. The DETERMINE trial will recruit both paediatric and adult patients with any rare cancer type, with eligible patients having …
Register for a PMHub account - PMLiVE
WEBAdding your company profile to PMHub is a simple process. FIll in the form to create an account. Verify your email to activate your account. Login and add your company details. We will monitor and approve your listing within a couple of days. First name. Last name. Email. Subscribe to our email news alerts.
Boehringer Ingelheim and Covant to collaborate on cancer ...
WEBMar 29, 2023 · Boehringer Ingelheim and Covant Therapeutics have entered into an exclusive research collaboration and worldwide licensing agreement to develop new cancer immunotherapies. The partners plan to develop a small-molecule inhibitor of RNA editing enzyme ADAR1 that could be used in combination …
Healthcare - PMLiVE
WEBEli Lilly commits further $6.5m to UNICEF for young people at risk of noncommunicable diseases. Jun 4, 2024 | News, Healthcare. The new funding builds on the company’s initial commitment of $14.4m in 2022. Read More.
Novo Nordisk acquires Embark Biotech in deal worth over €470m
WEBAug 31, 2023 · Novo Nordisk has announced its acquisition of Embark Biotech in a deal worth over €470m, marking another expansion of the Danish drugmaker’s cardiometabolic disease pipeline. The transaction gives the Danish drugmaker full rights to develop and commercialise Embark Biotech’s lead asset targeting …
Best practice in UK dermatology care celebrated at second
WEBNov 9, 2022 · The 2022 QiC Dermatology Awards also saw Dr Cedric Banfield from Peterborough win the Award for Outstanding Services in Dermatology. Debbie Woods, Country Medical Lead, Sanofi UK and Ireland said: “We are extremely proud to support the Quality in Care Dermatology awards for the second year. The QiC awards programme provides a great ...
AstraZeneca gains rights to Usynova’s KRAS inhibitor in deal worth ...
WEBNov 24, 2023 · AstraZeneca (AZ) has entered into an exclusive licence agreement with Chinese biotech Usynova for global rights to preclinical small molecule drug candidate UA022, with the deal worth almost $420m. UA022 targets the KRAS G12D mutation, the most common KRAS mutation in cancer and commonly found in pancreatic, colorectal and non-small cell lung ...